SCHEMBL29973154

SCHEMBL29973154

NC(=O)C(O)c1cccc(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.50
TRPM8 Q7Z2W7 5/20 0.47
ACP3 P15309 1/20 0.46
ADRA1D P25100 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
GLS O94925 1/20 0.44
HTR3E A5X5Y0 1/20 0.40
SLC22A2 O15244 1/20 0.40
SLC22A1 O15245 1/20 0.40
SLC22A3 O75751 1/20 0.40
HTR3B O95264 1/20 0.40
PLAU P00749 1/20 0.40
HTR3A P46098 1/20 0.40
HTR3D Q70Z44 1/20 0.40
HTR3C Q8WXA8 1/20 0.40
EPHX1 P07099 1/20 0.40
ADRB2 P07550 1/20 0.40
ADRB1 P08588 1/20 0.40
ADRB3 P13945 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5064609 1.00 PARP1 (0.50) PARP1TRPM8ACP3ADRA1DMEN1
SCHEMBL5064611 1.00 PARP1 (0.50) PARP1TRPM8ACP3ADRA1DMEN1
SCHEMBL6455240 1.00 PARP1 (0.50) PARP1TRPM8ACP3ADRA1DMEN1
SCHEMBL15774550 0.84 PARP1 (0.53) PARP1TRPM8ACP3ADRA1DMEN1
SCHEMBL1712936 0.82 LMNA (0.59) PARP1ACP3MEN1KMT2AGLS
SCHEMBL606571 0.82 LMNA (0.59) PARP1ACP3MEN1KMT2AGLS
SCHEMBL30147772 0.82 LMNA (0.59) PARP1ACP3MEN1KMT2AGLS
SCHEMBL606570 0.82 LMNA (0.59) PARP1ACP3MEN1KMT2AGLS
SCHEMBL7283486 0.81 PARP1 (0.50) PARP1TRPM8ACP3ADRA1DMEN1
SCHEMBL1353575 0.81 PARP1 (0.50) PARP1TRPM8ACP3ADRA1DMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220348583-A1 PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS HIBERCELL, INC. 2022-11-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348583-A1 PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS MAPKAPK2, MAPK4, MAP3K5 PARP1 1679/4885TRPM8 2816/4885ACP3 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.